Main competitors
1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Visibility Nbr of analysts
20
27
24
27
20
26
21
21
22
27
24
25
23
23
15
15
17
20
16
Average 22
Weighted average by Cap. 24
Other Pharmaceuticals